2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Journal of the American College of Cardiology

Volumn 68, Issue 13, 2016, Pages 1476-1488

  Yancy, Clyde W ^a   Jessup, Mariell ^a   Bozkurt, Biykem ^a   Butler, Javed ^a   Casey, Donald E ^a   Colvin, Monica M ^a   Drazner, Mark H ^a   Filippatos, Gerasimos ^a   Fonarow, Gregg C ^a   Givertz, Michael M ^a   Hollenberg, Steven M ^a   Lindenfeld, JoAnn ^a   Masoudi, Frederick A ^a   McBride, Patrick E ^a   Peterson, Pamela N ^a   Stevenson, Lynne Warner ^a   Westlake, Cheryl ^a  

^a NONE

Author keywords

ACC AHA Clinical Practice Guidelines; angioedema; angiotensin receptor blockers; angiotensin receptor neprilysin inhibitor; angiotensin converting enzyme inhibitors; beta blockers; focused update; heart failure; ivabradine; natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IVABRADINE; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; RENIN INHIBITOR; SACUBITRIL PLUS VALSARTAN;

ANGIONEUROTIC EDEMA; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CLINICAL PRACTICE; COUGHING; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; MEDICAL SOCIETY; MORBIDITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT PLANNING;

HEART FAILURE; HUMANS;

EID: 84990990458     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.05.011     Document Type: Article

References (40)

1. 1 ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. Available at: http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. 2010; American College of Cardiology and American Heart Association. Accessed April 7, 2016.
2. 2 Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (US). Clinical Practice Guidelines We Can Trust. 2011, National Academies Press, Washington, DC.
3. 3 Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. 2011, National Academies Press, Washington, DC.
4. 4 Jacobs, A.K., Kushner, F.G., Ettinger, S.M., et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 213–265.
5. 5 Jacobs, A.K., Anderson, J.L., Halperin, J.L., The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64 (2014), 1373–1384.
6. 6 Anderson, J.L., Heidenreich, P.A., Barnett, P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), 2304–2322.
7. 7 Arnett, D.K., Goodman, R.A., Halperin, J.L., et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. J Am Coll Cardiol 64 (2014), 1851–1856.
8. 8 Halperin, J.L., Levine, G.N., Al-Khatib, S.M., et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 67 (2016), 1572–1574.
9. 9 Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987), 1429–1435.
10. 10 Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 (1991), 293–302.
11. 11 Packer, M., Poole-Wilson, P.A., Armstrong, P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100 (1999), 2312–2318.
12. 12 Pfeffer, M.A., Braunwald, E., Moye, L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 (1992), 669–677.
13. 13 Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 (1993), 821–828.
14. 14 Køber, L., Torp-Pedersen, C., Carlsen, J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 (1995), 1670–1676.
15. 15 Cohn, J.N., Tognoni, G., Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001), 1667–1675.
16. 16 Pfeffer, M.A., McMurray, J.J.V., Velazquez, E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003), 1893–1906.
17. 17 Konstam, M.A., Neaton, J.D., Dickstein, K., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374 (2009), 1840–1848.
18. 18 Pfeffer, M.A., Swedberg, K., Granger, C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003), 759–766.
19. 19 McMurray, J.J.V., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
20. 20 Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999), 2001–2007.
21. 21 Packer, M., Fowler, M.B., Roecker, E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002), 2194–2199.
22. 22 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
23. 23 Eschalier, R., McMurray, J.J.V., Swedberg, K., et al. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol 62 (2013), 1585–1593.
24. 24 Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999), 709–717.
25. 25 Garg, R., Yusuf, S., Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 273 (1995), 1450–1456.
26. 26 Woodard-Grice, A.V., Lucisano, A.C., Byrd, J.B., et al. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 20 (2010), 532–536.
27. 27 Yusuf, S., Teo, K.K., Pogue, J., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. ONTARGET Investigators. N Engl J Med 358 (2008), 1547–1559.
28. 28 Yusuf, S., Teo, K., Anderson, C., et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Lancet 372 (2008), 1174–1183.
29. 29 Entresto [package insert]., 2015, Novartis Pharmaceuticals Corporation, Hanover, NJ.
30. 30 Solomon, S.D., Zile, M., Pieske, B., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
31. 31 Packer, M., Califf, R.M., Konstam, M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002), 920–926.
32. 32 Kostis, J.B., Packer, M., Black, H.R., et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17 (2004), 103–111.
33. 33 Vardeny, O., Miller, R., Solomon, S.D., Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2 (2014), 663–670.
34. 34 Messerli, F.H., Nussberger, J., Vasopeptidase inhibition and angio-oedema. Lancet 356 (2000), 608–609.
35. 35 Braunwald, E., The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol 65 (2015), 1029–1041.
36. 36 Ruilope, L.M., Dukat, A., Böhm, M., et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375 (2010), 1255–1266.
37. 37 Böhm, M., Robertson, M., Ford, I., et al. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT trial). Am J Cardiol 116 (2015), 1890–1897.
38. 38 Swedberg, K., Komajda, M., Böhm, M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376 (2010), 875–885.
39. 39 Fox, K., Ford, I., Steg, P.G., et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371 (2014), 1091–1099.
40. 40 Fox, K., Ford, I., Steg, P.G., et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 807–816.